艾德生物(300685.SZ):股東廈門科英擬通過大宗交易減持不超2%股份
格隆匯 8 月 18日丨艾德生物(300685.SZ)公佈,公司於2020年8月18日收到股東廈門科英出具的《關於股份減持計劃的告知函》,持公司股份1898.478萬股(佔公司總股本比例8.55%)的股東廈門市海滄區科英投資合夥企業(有限合夥)計劃在減持計劃公告之日起三個交易日後的六個月內以大宗交易的方式減持公司股份,減持數量不超過443.8845萬股(佔公司總股本比例2%)。
股東廈門市海滄區科英投資合夥企業(有限合夥)(“廈門科英”)不是公司控股股東、實際控制人,此次減持計劃實施不會影響公司治理結構和持續經營,不會導致公司控制權發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.